...diabetes. Orion Corp. , Eisai Co. Ltd. and Kyowa Hakko Kirin Co. Ltd. market Fareston toremifene citrate...

...and nonhuman primate infection models. Orion Corp. and Kyowa Hakko Kirin Co. Ltd. market Fareston toremifene citrate...

...conjunction with the deal termination, GTx sold its U.S. rights to breast cancer drug Fareston toremifene citrate...
...license to market Fareston in the U.S. Torrey Partners acted as financial advisor to GTx. Fareston...
...the U.S. to treat metastatic breast cancer in postmenopausal women. GTx reported $3.5 million in Fareston...

...rights to Orion's breast cancer drug Fareston toremifene citrate and Parkinson's disease (PD) drug Eldepryl selegiline. Fareston...
...June. Terms were not disclosed. Orion reported 2010 sales of €11.7 million ($15.6 million) for Fareston...

...in patients with non-small cell lung cancer (NSCLC). GTx also markets breast cancer drug Fareston toremifene citrate...

...FDA updated the label for breast cancer drug Fareston toremifene citrate to include a boxed warning about...
...to which it has U.S. rights only, from Orion. GTx markets toremifene 60 mg as Fareston...
...GTx Inc. (NASDAQ:GTXI), Memphis, Tenn. Orion Corp. (HSE:ORNAV; HSE:ORNBV), Espoo, Finland Product: Fareston toremifene citrate (formerly Acapodene...

...rights only, from Orion Corp. (HSE:ORNAV; HSE:ORNBV, Espoo, Finland). GTx markets toremifene 60 mg as Fareston...

...has U.S. rights only, from Orion Corp. (HSE:ORNAV; HSE:ORNBV). GTx markets toremifene 60 mg as Fareston...

...$40 million through the sale of 14.3 million shares at $2.80 in a follow-on. GTx's toremifene citrate...
...fractures in men with prostate cancer receiving androgen deprivation therapy. GTx also markets toremifene as Fareston...

...when its stock price was $3.19. GTx fell $0.33 (10%) to $2.86 on Wednesday. GTx's toremifene citrate...
...fractures in men with prostate cancer receiving androgen deprivation therapy. GTx also markets toremifene as Fareston...